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Abstract
Background: The GSK-3 genes (Gsk3a and Gsk3b) have been known to affect many
cellular processes and signaling pathways some of which are implicated in the growth
and development of the craniofacial skeleton.
Aim: The purpose of this study was to assess the effect of chondrocyte-specific deletion
of Gsk3a and Gsk3b on the size of the mandible and craniofacial skeleton in embryonic
mice.
Materials & Methods: Mice were bred to generate cartilage-specific Gsk3a and Gsk3b
KO mice. On embryonic day 18.5 (E18.5) the offspring were gathered by caesarian
section. Whole mount skeletal staining was completed on the specimens using Alcian
blue and Alizarin red. The antero-posterior (AP) dimension of the entire craniofacial
skeleton and the mandible was measured, along with the transverse dimension of the
cranial vault and the intramandibular angle for each embryo. The investigator was blind
to the genotype of embryos in each trial group. Immunohistochemistry was used to
detect and localize three proteins, Sox9, Beta-catenin, and Osteocalcin, in the bone and
cartilage of E16 mouse skulls.
Results: The specific removal of both Gsk3a and Gsk3b in prenatal cartilage of mice
leads to a significant reduction in the antero-posterior length of the total craniofacial
skeleton and mandible when compared to wildtype mice. Cartilage-specific
Gsk3a/Gsk3b KO mouse embryo display no significant change in the transverse width of
the cranial vault. A significant increase in the intramandibular angle is seen in the KO
mice when compared to the wild type mice.
Conclusions: Loss of both GSK-3 isoforms in prenatal mice results in significant changes
to the size and shape of the facial skeleton and cranium.
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Summary for Lay Audience
Orthodontics is a field which utilizes bone growth to move teeth, expand the
upper jaw, and to align the upper and lower jaws in a manner which is harmonious to
the rest of the skull. Currently mechanical approaches employing brackets, wires,
auxiliaries, appliances, and surgical methods are the primary means to manipulate bone
growth and achieve orthodontic goals. With advances in molecular medicine research,
biological approaches including molecular therapy may provide new avenues to
manipulate bone growth. Molecular interventions such as those that target GSK-3, an
enzyme involved in skeletal development, may assist orthodontists to treat patients in
which unstable dental camouflage or orthognathic surgery are the only viable options.
Previous studies have looked at the way the GSK-3 genes affects bone growth, which is
commonly done by removing the gene. This study was designed to see if removing both
GSK-3 genes from a specific structural component (cartilage) in mice before they are
born would change the shape and size of their head or lower jaw. Multiple prenatal
mouse skulls were measured using images taken on a microscope of skulls stained to
make bone more conspicuous. The measurements of the mice missing the GSK-3 genes
were compared to normal mice gathered from the same litter. This study found the
mice which had the GSK-3 genes removed had a smaller head size in length but not in
the width dimension. The mutant mice also had a smaller bottom jaw in the length
dimension but bigger in the angular width dimension. This study showed that the GSK-3
gene can alter the growth and development of the craniofacial skeleton in prenatal
mice.
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Chapter 1

1

Review of the Literature

1.1 History
In 1980 an enzyme that inactivated glycogen synthase, a key regulator of
glycogenesis, was discovered in rabbit skeletal muscle cells.1 At the time its only known
role was the regulation of glycogenesis. It was consequently named glycogen synthase
kinase 3 (GSK-3). Initially, GSK-3 did not garner much attention from the research
community. It was not until a decade later in 1992 when Hanger et al’s research on tau
phosphorylation first shone the spotlight on GSK-3 and identified GSK-3 as being a key
contributing enzyme in the abnormal phosphorylation of the microtubule associated
protein tau. Tau itself is responsible for the development of neurofibrillary tangles seen
in Alzheimer’s disease.2 Another advance in research 4 years later found that the
commonly prescribed bipolar disorder medication lithium selectively inhibited GSK-3.3
With this knowledge, pharmaceutical companies and research groups began to focus
their efforts on preparing GSK-3 as a therapeutic target.4, 5 Current literature now
recognizes that GSK-3 has a role in multiple signalling pathways including regulation of
cell development, cellular architecture, the cell cycle, and apoptosis.6 Due to its broad
spectrum influence it has been linked to a diverse array of diseases including diabetes
and insulin resistance, cancer, rheumatoid arthritis and Alzheimer’s disease.6

1.2 GSK-3 Structure
The enzyme is a serine/threonine kinase that is conserved across all eukaryotes
and is expressed in almost all tissue types.7 In primitive organisms like nematodes, GSK3 is encoded by a single gene. In mammals, GSK-3 is present as two specific proteins,
GSK-3α and GSK-3ß, which are homologous proteins derived from different genes.7
Furthermore, alternative splicing of GSK-3ß mRNA produces two isoforms GSK3-ß1 and
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GSK-3ß2.8 GSK-3ß2, unlike the other two ubiquitous isoforms, is primarily expressed in
neuronal tissue and currently has an unclear role. Among vertebrates, only birds share
this property, retaining the GSK-3ß protein.9 It is believed that the evolution of GSK-3
isoforms is linked to the rise of vertebrates and in particular the development of their
central nervous system.5 The molecular weight of GSK-3α protein is 51 Kilodaltons,
while GSK-3ß is 47 Kilodaltons, the disparity due to a glycine rich extension present at
the N-terminus of GSK-3α.10 The structure of GSK-3’s catalytic domain contains a Nterminal domain comprised of β-strands in a β barrel conformation and a C-terminus
comprised of α-helices.11 The general structure is akin to other protein kinases.11
Between the N and C terminus is the C-helix and activation loop, which together create
the binding site for the substrate to receive the gamma phosphate from ATP in the
process of phosphorylation.12 At the substrate binding site both GSK-3α and GSK-3ß
possess lysine residues which catalyze the transfer of gamma phosphate to the
substrate.13 It has been shown through point mutation of specific residues that the Nterminus is expendable, whereas, the deletion of the C-terminus creates destabilization
of GSK-3’s tertiary structure.13 It is believed that targeting the C-terminus is key to
creating an isoform-specific GSK-3 therapeutic inhibitor.13 Despite being structurally
alike, the proteins GSK-3α and GSK-3ß are not completely functionally identical.
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Figure 1: Crystallographic structure of human GSK-3ß 11

1.3 Function and Regulation
GSK-3 predominantly functions as a negative regulator in numerous anabolic
pathways.14 It has also been known to modulate cell proliferation, differentiation,
neuron development, immune and inflammatory response, and bone formation. GSK-3
has been linked to the canonical Wnt/Beta-catenin pathway15, the osteogenesisassociated Runx2 pathway16, Hedgehog signalling pathway17 and many others.18 The
primary mechanism in which GSK-3 acts is through phosphorylating proteins in cellular
pathways and inhibiting their downstream effect.14 An unusual characteristic of GSK-3
compared to other protein kinases is its preference for primed substrates that have
been acted upon by another kinase. GSK-3’s affinity for pre-phosphorylated substrates is
seen as another potential target point for therapeutic inhibitors.19 In certain pathways
like the Wnt/beta catenin pathway both isoforms are functionally redundant.20 This was
demonstrated when Doble et al. found Wnt/beta catenin signaling to be normal despite
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an absence of compensatory upregulation in GSK-3 protein levels in embryonic stem
cells deficient of either the GSK-3α or GSK-3ß isoform alone.20 Only when cells lacked
alleles for both isoforms was beta catenin signaling affected.20 In other pathways the
individual influence of each isoform is less clear.21
Another atypical characteristic of GSK-3 is that in its basal state it is constitutively
active in cells and is generally rendered inactive upon phosphorylation 14. Regulation
through phosphorylation of both isoforms occurs at two sites involving either a tyrosine
or serine residue. Inactivation of GSK-3 occurs when the N-terminus is phosphorylated
at Ser-9 in GSK-3ß or Ser-21 in GSK-3α.22 Kinases that are known to inhibit GSK-3
through phosphorylation of serine include protein kinase A, PI3 kinase regulated
Akt/PKB, p70 S6 kinase, and protein kinase C.15 On the other hand, GSK-3 activity is
augmented when tyrosine phosphorylation of Tyr-216 in GSK-3ß, and Tyr-279 in GSK-3α
occurs in the catalytic domain.22 Kinases known to phosphorylate tyrosine residues and
increase enzymatic activity of GSK-3 include Fyn, Pyk2, and Csk.22 Regulation of GSK-3
can also be independent of serine or tyrosine phosphorylation, although uncommon, is
a mechanism retained by the Wnt signaling pathway. GSK-3 antagonizes the canonical
Wnt signalling pathway 23, thus for the Wnt pathway to function it requires
downregulation of GSK-3. The mechanism which is not fully understood is believed to
occur through complex formation via protein:protein binding interactions and
sequestration of GSK-3 inside multivesicular endosomes. The capture of GSK-3 in
endosomes likely prevents it from accessing its many cytosolic substrates.17, 24
Additionally, regulation of GSK-3 can be completed through intracellular
localization. The activity level of GSK-3 varies depending on its compartmental
localization. Although GSK-3 is more abundant in the cytoplasm, it is also present in the
nucleus and mitochondria where it is more active.25 The movement of GSK-3 outside of
the nucleus has been shown to correlate with a decrease in phosphorylation of GSK-3
nuclear substrates.25 Cellular processes like apoptosis have been associated with an
increase in the nuclear localization of GSK-3. Exporting GSK-3 out of the nucleus is one
way of disrupting its ability to phosphorylate nuclear targets and thus promoting cell
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survival.26 Frat/GBP (frequently rearranged in T-cell lymphomas/GSK-3 binding protein)
is a binding protein known to regulate GSK-3 localization by facilitating its nuclear
export. One of the potential targets for therapeutic isoform inhibitors is believed to be
the N-terminal region of GSK-3, which contains the ATP-binding domain and also
contributes to the localization of GSK-3. A study conducted by Azoulay-Alfaguter et al.
found that while GSK-3ß normally moves between cytoplasm and the nucleus, GSK-3α is
barred from the nucleus, a characteristic exclusive to mammalian GSK-3α.27 The
researchers found that by deleting the glycine rich N-terminus of GSK-3α, the alpha
isoform accumulated in the nucleus. They hypothesize that GSK-3 isoform regulation via
localization is mediated by the glycine rich N-terminus, which is only present in GSK3α.27

1.4 Mice Knockout Models
Research shows when the Gsk3b isoform is made inoperative (global knockout)
in mice it results in craniofacial abnormalities and embryonic lethality due to severe liver
degeneration28, 29, in contrast to global Gsk3a knockout mice which are viable and have
no visible craniofacial defects.21, 30 Furthermore, mice which are heterozygote for Gsk3b
are viable, but present with increased anxiety, reduced exploration, and skeletal bone
mass changes similar to those displayed in cleidocranial dysplasia (CCD).16, 31, 32 The
viability of mouse embryos displaying increased activity of GSK-3ß was tested by Deak et
al. in a glycogen synthase kinase 3ß interaction protein (GSKIP) model.33 GSKIP
conventionally facilitates the serine phosphorylation of GSK3-ß by Protein Kinase A
(PKA) thereby reducing GSK-3ß activity. In this model, GSKIP deficient mutant mice
embryos at day 10.5 (E10.5) display increased GSK-3ß activity, which ultimately leads to
failure of palatal shelf fusion and perinatal lethality.33 The phenotypic outcome of GSKIP
deficient mice, however, differs from knock-in transgenic mice which display a
constitutively active GSK-3ß that is immune to phosphorylation.34, 35 These transgenic
mice are viable and show no craniofacial defects but do exhibit neuronal deficiencies
and a reduced brain size.34, 35
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Organ specific ablation of GSK-3 elucidates the importance of GSK-3 regulation
throughout the body. Howard et al. demonstrated this concept when renal proximal
tubule specific Gsk3b knockout mice conditioned to nephrotoxic injury displayed
accelerated cell proliferation and healing.36 Moreover, the phenotype that is expressed
in knockout mice can vary depending on the cells in which GSK-3 is deleted. In
chondrocyte-specific GSK-3ß deficient mice the phenotype that is demonstrated is the
same as wild-type mice, aside from elevated GSK-3α enzyme levels.37 The absence of
skeletal abnormalities may indicate a compensatory mechanism by GSK-3α.37 The
summation of current literature shows that the phenotype and clinical manifestation of
the GSK-3 mutant does not strictly depend on whether the GSK-3 enzyme is present or
not. It depends on a variety of factors including the timing of the ablation, post-natal or
prenatal, the pathway by which GSK-3 is altered, the organ in which the enzyme is
affected, the cells in which it is removed and the isoform which is targeted. All this
information must be taken into consideration in order to develop therapies that target
GSK-3 with safe clinical outcomes.

1.5 Craniofacial Skeleton
One of most unique and identifying structures in humans and mammals is the
craniofacial complex. The complex consists of the head, the face and the oral cavity.
Each constituent of the craniofacial complex can be categorized into its skeletal
subcomponent. The posterior portion of the complex is comprised of the cranium a
structure formed by the conjunction of the cranial vault and the cranial base.38 The
anterior portion, the face, is comprised of the nasomaxillary complex and the mandible.
The development of the craniofacial skeleton occurs through both endochondral and
intramembranous ossification.
Endochondral ossification is a process which begins when mesenchymal stem
cells differentiate into chondroblasts to form a cartilage intermediate.39 Chondroblasts
differentiate into chondrocytes which secrete alkaline phosphatase, an enzyme that acts
to initiate deposition of minerals on the cartilage template.39 Over time the
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chondrocytes undergo apoptosis and create cavitations which are invaded by blood
vessels. The blood vessels serve as a source for osteoprogenitor cells, which
differentiate into osteoblasts that produce bone mineral around the cartilage
template.39 Intramembranous ossification, unlike endochondral ossification, does not
require the formation of a cartilage template. Instead, the process involves
mesenchymal stem cells differentiating directly into bone matrix depositing
osteoblasts.40
The cranial base is sculpted by endochondral ossification of the
chondrocranium, which is the cartilaginous structure derived from mesoderm that
serves as a template to be replaced with new bone.38, 41 On the other hand, the cranial
vault develops through intramembranous ossification. This process involves either
paraxial mesoderm (parietal bones) or neural crest derived mesenchymal cells (frontal
bones) that condense to produce osteoblasts which deposit osteoid matrix.38, 41 Fate
mapping and lineage tracing in mice show that the bones which make the
viscerocranium including the maxilla and mandible are formed from neural crest cells
(NCC) that have localized to the first pharyngeal arch.42, 43 The NCC undergo both
intramembranous and endochondral ossification.38 During embryogenesis neural crest
cells migrate towards the developing brain and into the first three pharyngeal arches,
which further develop to form the facial skeleton.38 The anatomical and physiological
formation of the pharyngeal arches has been highly conserved through vertebrate
evolution, with only the number of arches varying between species.44 The first arch
gives rise to the maxilla and mandible, two structures which articulate together to give
mammals the ability to perform mastication, respiration, and vocalization.44 Both the
upper and lower jaw are formed during embryogenesis from their respective anatomical
prominences located in the first pharyngeal arch. These prominences include the
frontonasal, medionasal, nasolateral, maxillary, and mandibular prominence. Through
systematic and unified development, the prominences fuse to form the face. Failure of
the fusion process can result in orofacial clefts.45
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Figure 2: 3D reconstruction of micro computed tomography image of the mouse skull at
birth.46

1.6 Prenatal Growth of the Mandible
The elements influencing the final arrangement of the mandible are more convoluted
than those of the cranial vault. The shape and growth rate of calvaria bone is primarily
governed by brain enlargement and cranial sutures.47 The mandible is a unique structure
of the craniofacial complex in that it is formed from both intramembranous and
endochondral growth.48 The mandible develops from the neural crest cells which have
migrated to the first pharyngeal arch (mandibular arch). The NCC respond to signals from
the primary germ layers of the first pharyngeal arch, to first condense, then differentiate
into chondrocytes and osteoblasts.38 The chondrocytes organize into two hyaline based
bilateral cartilaginous rods which are referred to as Meckel’s cartilage (MC). In mice MC
forms at approximately E12.5 and begins to degenerate at E16.49 The proximal ends of
MC form the bilateral template for the malleus and incus bones of the middle ear.48
Whereas the distal ends of MC converge and fuse, to eventually form the template for
the symphysis of the mandible48. The molecular mechanisms which control the
development and regression of MC are still unclear 48, however, it is well established that
the function of MC is to serve as a template for ossification.50
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Research shows that in the absence of MC the mandible still does form with relatively
normal gross morphology and bone formation. However, the mandibles in mutant mice
lacking MC are smaller, suggesting MC influences the size and not the initiation of bone
formation.51 The body of the mandible ossifies through intramembranous bone growth
on the outer surface of MC, with the first sign of osteoid tissue at the paired plates being
seen at E13.5.49 By E16.5 both mandibular plates lengthen to meet at the symphysis and
have enclosed the alveolar nerve and MC in the process.49 The mandible ossifies from its
external aspect inward surrounding MC concomitantly as it grows along the anteroposterior axis.49 The formation of the condyle and coronoid process occurs through
endochondral ossification, these structures do not rely on the scaffold provided by
Meckel’s cartilage.38 They instead, rely on mandibular condylar cartilage (MCC), which is
classified as secondary cartilage. The axial and appendicular skeleton, by contrast,
develop through the scaffold provided by primary cartilage. 38
Primary and secondary cartilage differ histologically and in place of origin. Secondary
cartilage at the condyle histologically presents as undifferentiated prechondroblasts, with
the cell pattern of proliferation being appositional. Primary cartilage has chondrocytes
that demonstrate interstitial cell proliferation.52, 53 Both primary and secondary cartilage
contain type II collagen, however, only secondary cartilage contains type I collagen, a
component which functions to provide tensile strength for the extracellular matrix.54
Primary cartilage develops from the primordial skeletal cartilage, whereas secondary
cartilage at the mandible is believed to develop from alkaline phosphatase (ALP)
expressing progenitor cells located on the periosteum.55, 56 A study conducted by Shibata
et al. described the endochondral ossification of the condyle as similar to that found in
long bones.56 At E14.5 chondrocytes located in MCC undergo hypertrophy followed by
calcified bone tissue forming a bone collar around the MCC.56 The hypertrophic
chondrocytes undergo apoptosis, leaving gaps in the mineralized extra cellular matrix.
These openings are the cartilage lacunae which serve as the port of entry for blood
capillaries to invade bringing in osteogenic cells. The osteogenic cells differentiate into
osteoblasts to lay down bone around the calcified cartilage eventually forming the
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condyle.56 Histologically, secondary cartilage is first detected at E14.5, with endochondral
bone formation at the condyle occurring at E16.56 Intramembranous ossification
contributes to the initial stages of mandible development with the later stages
undergoing endochondral ossification of the secondary cartilage and developing into the
condyle and angular process of the mandible.57 MCC will serve as the site for
endochondral growth until the late adolescent years in humans.58

Figure 3: Mandibular growth over time measured from point Articulare (AR) to point
Menton (Me).59
A variety of factors influence overall growth of the mandible including fetal jaw
movement prenatally. In humans the jaw-opening reflex initiates at week 8.5, while in
mice prenatal jaw movement begins at E16. Studies have shown that restricting fetal jaw
movement reduces endochondral ossification of the condyle which can ultimately inhibit
normal mandibular growth.60, 61 Experiments examining mice post-natally at 3 weeks of
age until 33 weeks of age have demonstrated that the size and shape of the mandible in
mice may be dependent on the consistency of the food they eat.62 Another study found
that continuously trimming the lower incisors by 1mm increased posterior condylar
growth during the posterior axial rotation of the condyle as the mandible was advanced.
63

The environment seems to play an important role in the growth and development of

the mandible both prenatally and postnatally. While researchers and clinicians have
readily manipulated the environment to influence the development of the mandible
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whether that be through a Herbst or a bilateral sagittal split osteotomy, the new path
forward in manipulating the growth of the mandible appears to lie in molecular therapy.

Figure 4: Anatomy of the mouse mandible in the sagittal viewpoint. Dashed line divides
alveolar region from ascending ramus 64.

1.7 GSK-3 Regulated Pathways and Bone Growth
Genetics plays a major role in craniofacial and mandibular growth. GSK-3 is known
to modulate transcription and growth factors involved in prenatal bone growth. Facial
development is influenced by the Wnt signaling pathway, which is in turn regulated by
GSK-3. During growth, structures of the face react to Wnt signaling with enhanced cell
proliferation in order to increase mass. Studies show that vertebrates with a pronounced
midface such as avian and mice species show increased Wnt responsiveness at the
midline zone within the frontonasal process supporting more of an antero-posterior
growth pattern of the face.45, 65 In humans, by contrast, Wnt signalling in the maxillary
and mandibular processes leads to the development of flat, broad midfaces and results
in more lateral growth of the face.45
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Sox9 is a transcription factor that regulates chondrocyte differentiation from
mesenchymal cells, a process that is critical for endochondral ossification during
embryogenesis.66 Literature shows that Sox9 knockout mice do not form MC, and
although the mandible does form, it is much smaller than in control mice.51 Sox9 is a wellknown substrate of GSK-3. Phosphorylation of Sox9 by GSK-3 facilitates the binding of
FBW7 which subsequently results in the ubiquitination and degradation of Sox9.
Interestingly removal of GSK-3 from different germ line cells can change Sox9 levels. Bali
et al. found that post-natal cartilage-specific GSK-3 deficient mice show decreased levels
of Sox9 in growth plate and articular cartilage and skeletal growth retardation.67 Gillespie
et al. found that bone-specific knockout of Gsk3b resulted in mice with shorter bones and
dwarfism similar to cartilage-specific Gsk3 KO mice, despite Sox9 being upregulated in the
cartilage of these mice.68 In vitro pharmacological inhibition of GSK-3 by contrast shows
increased bone growth.37 The authors propose that the contradictory results may be due
to a complex interplay of local skeletal effects and metabolic changes in GSK-3 deficient
mice.68
Runx2 is another osteogenesis modulator known to be regulated by GSK-3. Runx2 is a
transcription factor that regulates expression of genes involved in the development of
teeth, as well as intramembranous and endochondral bone formation.69 Haploinsuffiency
in the Runx2 gene results in compromised osteogenesis and clinical manifestations of
cleidocranial dysplasia (CCD) in both humans and mice.70 Kugimiya et al. used Runx2
deficient mice to demonstrate Gsk3b’s ability to suppress Runx2’s transcriptional activity.
The researchers crossed mice to produce Runx2+/- heterozygotes which displayed
characteristics resembling human CCD, including delayed closure of the fontanelles and
hypoplastic clavicles. They then administered lithium chloride (a selective inhibitor of
GSK-3ß) to the embryos through the pregnant dams, orally starting at E7.5 to 3 weeks of
age. At 3 weeks of age they found the GSK-3ß inhibitor to have rescued the Runx2+/deficient mice from displaying CCD characteristics.16 The authors believe that attenuation
of Runx2 by phosphorylation via GSK-3 is just one of many molecular pathways that GSK3 uses to negatively regulate osteogenesis.
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A study conducted by Kapadia et al. brings light to the variable effects of GSK-3,
which is commonly shown to inhibit signaling needed for bone development. Fibroblast
growth factor 18 (FGF18) was identified as a potential mediator of GSK-3 activity in
metatarsal culture. In this study researchers harvested metatarsals from E15.5 embryos
and treated them in organ culture with two GSK-3 inhibitors, lithium or SB216763. The
researchers found that by inhibiting GSK-3 there was a significant reduction in
chondrocyte and osteoblast differentiation, and chondrocyte proliferation, but there
was a contrasting increase in perichondrial cell proliferation. The researchers
hypothesized that the inhibition of GSK-3 induced Wnt/Beta catenin signaling, a
pathway which is known to have complex effects displaying both an increase and
decrease of chondrocyte differentiation. Kapadia et al. found that stimulation of the
metatarsals with FGF18 produced a similar phenotype to GSK-3 inhibition. To determine
whether metatarsal endochondral bone growth changes resulting from GSK-3 inhibition
were mediated by changes in FGF18 expression, the researchers inhibited GSK-3 in
metatarsals deficient of FGF18 receptors. The experiment revealed that inhibition of
GSK-3 in metatarsals lacking FGF18 receptors did not reproduce the phenotype
produced in metatarsals with normal FGF18 receptor expression. The researchers
concluded that one of the molecules through which GSK-3 regulates endochondral bone
growth is by mediation of FGF18.71
NCC play a vital role in the development of craniofacial skeleton, particularly the
viscerocranium. The movement of NCC into the first pharyngeal arches initiates their
differentiation into cells which will eventually form the bone and cartilaginous tissue of
the viscerocranium. Recent literature suggests GSK-3 plays a role in the migration of
NCC from the neural tube to the first branchial arch (mandibular arch). Malagon et al.
established that deletion of neural crest-specific GSK-3α and GSK-3ß immobilizes the
NCC in the neural tube. Failure of migration of NCC to the facial prominences and
branchial arches due to in vivo loss of GSK-3α and GSK-3ß resulted in fatality of the mice
by E11.5.72 In order to examine the developmental effects of GSK-3 on NCC migration
and craniofacial growth the researchers treated Xenopus (frog) embryos with the GSK-3
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inhibitor 6-bromoindirubin-3’-oxime (BIO) between stages 12.5 and 19. They found that
inhibition of GSK-3 resulted in concurrent loss of twist1 expression. Changes in face
shape were illustrated including narrowing of the transverse width of the head, a
decrease in the antero-posterior dimension anterior to the eye, and loss of the oral
cavity. Discontinuing treatment of the GSK-3 inhibitor at stage 19 allowed for some
recovery of twist1 expression, which corrected the craniofacial size abnormalities to
some degree. 72 The relationship between GSK-3 and twist1 expression could provide
valuable information in the treatment of Saethre Chotzen syndrome, a disorder
characterized by craniosynostosis and syndactyly with many individuals expressing a
mutation in the TWIST1 gene.
Other factors involved in bone development and craniofacial growth include Sonic
hedgehog (Shh), Bmp4, and endothelin-1. Current literature shows that GSK-3 has been
implicated in the regulation of these signalling pathways in other physiological systems
73,74, 75

, however, there is not enough research linking these factors to GSK-3 in the

realm of craniofacial growth and development. There is no direct evidence in the
current literature associating mandibular growth, a process governed by
intramembranous and endochondral ossification, with GSK-3. GSK-3 is, however, an
enzyme which regulates bone developmental pathways, and many genes that are
substrates of GSK-3 have been shown to impact mandibular growth.76–79

1.8 GSK-3 and Dental Applications
A great deal of research is focusing on mapping the effects of GSK-3 for clinical use.
Inhibitors of the enzyme are being investigated for potential in treating diabetes 4,
Alzheimer’s disease 80, osteoporosis 81, as well for dental and orthodontic applications
82

. Many of the GSK-3 inhibitors including lithium, L803-mts, and Tideglusib, upregulate

the Wnt signaling pathway and increase Beta-catenin levels, a protein which is known to
have a positive effect on bone anabolism.5, 19, 83 In the field of dentistry an investigation
on the off-label use of GSK-3 inhibitors has shown promise in repairing damaged
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dentine.84 To evaluate the remineralization effects of GSK-3 inhibitors researchers
created a site of injury just above the pulp in mice molars using a dental bur, then
inserted a sponge soaked with a GSK-3 inhibitor into the prepped site and left it for 4-6
weeks. Three GSK-3 inhibitor experimental groups were compared to a control and a
mineral trioxide aggregate (MTA) treatment group. At the end of the study period, the
researchers found that the GSK-3 inhibitor groups had 2 times greater reparative
dentine mineralization than the control and 1.7 times greater than the MTA group.
Furthermore, the researchers calculated the equivalent dose of Tideglusib (GSK-3
inhibitor) in humans and found the dose required for human tooth remineralization
would be far below the allowed maximum systemic concentration.84
Research has also shown that GSK-3 can modulate both local and systemic
inflammation.85 Data on this subject can prove to be vital in learning how to treat
bacteria-induced periodontitis. Adamowicz et al. used a previously established
Porphyromonas gingivalis (P.gingivalis)-induced bone loss model to examine the effects
of SB216763 (GSK-3 inhibitor) on the inflammatory response that characterizes
periodontitis. The researchers discovered that mice treated with SB216763 had
significantly less bone loss compared to the P.gingivalis bone loss group. The clinical
findings were reinforced with immunohistochemistry and an evaluation of inflammatory
mediators which indicated a decrease in systemic cytokines, local neutrophil infiltration,
and IL-17 expression.86 The results indicate that alveolar bone loss can be decelerated
by a GSK-3 inhibitor, putatively via modulation of the immune system.
Moving teeth in orthodontics uses mechanical loading to generate a localized
inflammatory reaction that triggers bone remodeling; controlling this inflammatory
response through GSK-3 could possibly alter the speed in which teeth move.
Orthodontic studies have examined the use of GSK-3 inhibitors on force-induced bone
formation. The results of Mao et al. have shown an increase in bone formation after the
local delivery of lithium on the tension side of teeth during orthodontic tooth
movement.87 One of the primary reasons for relapse after maxillary expansion is skeletal
instability due to insufficient bone formation at the palatal suture.82 Two studies have
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also shown positive effects of GSK-3 inhibitors on enhancing bone growth during palatal
expansion. Tang et al. assessed the effects of lithium fed orally in rats during midpalatal
expansion and found there to be an increase in new bone formation during expansion.88
Similarly, Jiang et al. found that the GSK-3 inhibitor SB-415286 stimulated new bone
formation in the premaxilla when delivered locally by injection during the process of
expansion.89 Together these studies show the potential for targeting GSK-3 to improve
the outcomes of orthodontic treatment.

1.9 Problem Statement
Despite GSK-3’s vast sphere of influence on numerous cellular processes, and the
research community’s great interest in the enzyme, there are only a limited number of
studies assessing GSK-3’s role in the development of the craniofacial complex.
Furthermore, there are even fewer studies assessing the cartilage-specific effects of
GSK-3 on the prenatal formation of the craniofacial complex. The field of orthodontics
prides itself in achieving harmony and balance between the bones of the viscerocranium
and the cranial base, a paradigm emphasized in the 60s by Enlow et al. 90 which still
stands today. Studying the effects of GSK-3 on the formation of the bones of the head
can assist in providing new treatment modalities geared at correcting skeletal
discrepancies whether they be craniosynostosis, hemifacial microsomia, or a
retrognathic mandible.

1.10 Purpose
The primary purpose of this in vitro investigation is to assess the effect of
chondrocyte specific deletion of Gsk3a and Gsk3b in embryonic mice on the size of the
mandible and the antero-posterior (AP), and transverse size of the prenatal craniofacial
skeleton at E18.5. A greater understanding of the role of GSK-3 in the determination of
the size of the cranium and mandible may contribute to the development of GSK-3
targeting molecules in the field of orthodontics.
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1.11 Hypothesis
Gsk3a and Gsk3b knockout mice will have a smaller AP length of the mandible and
skull as well as a smaller transverse width compared to the control mice. Gsk3a and
Gsk3b knock out mice will also display histological differences compared to control
mice.
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Chapter 2

2

Materials and Methods

2.1 Mouse Breeding
Floxed mice (Mus musculus) Gsk3afl/fl and Gsk3bfl/fl contain the DNA sequence for
Gsk3a and Gsk3b flanked by LoxP sites, DNA sequences that undergo recombination in
the presence of Cre recombinase (Cre+). The generation of floxed Gsk3afl/fl and Gsk3b fl/fl
and transgenic mice expressing Cre recombinase under the control of the mouse type II
collagen promoter (Col2a1) has been described elsewhere 30, 91, 92. Mice homozygous for
both Gsk3afl/fland Gsk3bfl/fl alleles were generated (Gsk3afl/flGsk3bfl/fl) by first breeding
the individual floxed lines to each other. The progeny of this mating would be
heterozygous for each floxed allele (Gsk3afl/+Gsk3bfl/+). The desired homozygotes are
produced by breeding heterozygotes to each other. The homozygous floxed mice
(Gsk3afl/flGsk3bfl/fl) were then crossed with mice expressing Cre recombinase under the
control of the mouse Col2 1 promoter to produce Gsk3afl/+Gsk3bfl/+ Col2 1Cre+/- mice.
These mice were then backcrossed with homozygous Gsk3afl/fl Gsk3bfl/fl mice to generate
Gsk3afl/+Gsk3bfl/fl Col2 1Cre+/- mice. Male Gsk3afl/+ Gsk3bfl/flCol2 1Cre+/- were bred to
female Gsk3afl/flGsk3bfl/fl to generate the offspring that were examined. The offspring
genotypes were: Gsk3afl/flGsk3bfl/fl (control), Gsk3afl/+ Gsk3bfl/fl (control), Gsk3afl/+Gsk3b
fl/fl

Col2 1Cre+/- (alpha heterozygote) and Gsk3afl/flGsk3bfl/fl Col2 1Cre+/- (knockout). On

embryonic day 18.5 (E18.5) the pregnant dams were euthanized by CO2 inhalation and
the offspring were gathered by caesarian section. All procedures involving the mice in
this study were approved by Western University’s Animal Care Committee and the
working subcommittee of the Western University Council for Animal Care (UCAC).
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2.2 PCR and Genotype Determination
Genotype of the offspring was determined by polymerase chain reaction (PCR)
utilizing DNA from soft tissue samples obtained from the skin of each embryo. PCR for
genotyping uses primers specific to the GSK-3 allele being studied, the process amplifies
the normal or mutant allele which is then observed and analyzed as bands after agarose
gel electrophoresis. Primer sets were used to detect the presence of floxed Gsk3a,
floxed Gsk3b and cre recombinase. The primer set 5’- CCCCCACCAAGTGATTTCACTGCTA
-3’ and 5’- CTTGAACCTTTTGTCCTGAAGAACC -3’ was used for Gsk3a, 5’GGGGCAACCTTAATTTCATT -3’ and 5’- GTGTCTGTATAACTGACTTCCTGTGGC -3’ for Gsk3b,
and 5’ CCT GGA AAA TGC TTC TGT CCG 3’ and 5’ CAG GGT GTT ATA ACA ATC CC 3’ for
Cre recombinase. The PCR protocol starts with an initial denaturation step at 95 °C for 3
minutes, followed by 35 cycles of denaturation-annealing and extension (95°C, 15
seconds; 60°C, 30 seconds; 72°C, 1 minute). A final extension step of 72°C for 10
minutes, followed by 4°C maintenance step completes the reaction. The amplified DNA
was then assessed on a 1.5% agarose gel, Gsk3a floxed alleles display a band of 650bp
whereas the wild type allele of Gsk3a was 500bp. Gsk3b floxed alleles display a band of
700bp versus a wild type allele of 500bp. Cre recombinase positive animals display a
single band of 391bp. Mice without Cre recombinase show no band. Genotype was
revealed to the investigator after craniofacial measurements of each offspring were
made.

2.3 Skeletal Staining
Whole mount skeletal staining allows one to evaluate the shape and size of
skeletal components. The process differentially stains bone and cartilage, as a result one
can assess the constituents and maturation level of the specimen. The cationic dye
Alcian blue binds glycosaminoglycans and glycoproteins secreted by chondrocytes
during endochondral ossification. The anionic dye Alizarin red binds positively charged
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calcium ions, a metal which is highly concentrated in bone. Visually, bone is stained red,
and cartilage is stained blue on the specimen.93 At E18.5 embryonic mice were skinned,
eviscerated and intrascapular fat deposits removed. The embryos were then dehydrated
in 95% ethanol overnight and then placed in acetone for further fatty tissue
solubilization and tissue permeabilization. Two different staining procedures were used
to stain the skeletons, the first, as described in McLeod et al. 94, and the second, as
described in Rigueur and Lyons.93 After the staining was completed, the skulls were
incubated in a solution of KOH in glycerol to enhance transparency and prevent collapse
of the skulls. Once appropriate transparency was achieved the specimens were placed in
a solution containing 1:1 glycerol/ethanol and images were taken.

2.4 Image Capture and Analysis
The investigator was blind to the genotype of embryos in each trial group. Ten
litters (trials) consisting of a total of 39 mice were examined in this study. Images of
stained heads in the sagittal and coronal view for each littermate were taken at 8x
magnification using a Leica S6 D microscope and a Leica EC3 camera using the Leica
Application Suite Software (Leica, Wetzlar, Germany). Scale calibration on the
microscope was completed by using an image of a line gauge. The craniofacial skeleton
of each stained head was analyzed using ImageJ software with four measurements
being made. Measurements were excluded in embryos in which the skull was distorted
(collapse of the cranial vault), a fractured bone segment was present, or if the landmark
could not be identified. The first measurement, the anterior-posterior (AP) length, was
recorded twice from two independent measurements one made in a sagittal viewpoint
(Fig. 5A) and the other made in a coronal viewpoint (Fig. 5C). The AP length connects the
most anterior portion of the premaxilla to the tangent of the most posterior portion of
the exoccipital bone. The second measurement (transverse) also recorded twice from
two independent measurements, one from the coronal and one from caudal viewpoint,
it connects the most distal aspects of the left and right parietal bones. The third
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measurement (mandibular length) is made in the sagittal view and connects the inferiordistal condyle point to the most anterior-inferior point on the symphysis of the left
mandible (Fig. 5C). The fourth measurement (intramandibular angle) is made in the
caudal viewpoint (Fig. 5B) and is taken of the angle formed between the distal most
points of angular processes with the midsymphysis being the common vertex.

2.5 Toluidine Blue Staining
Staining with toluidine blue allows the visualization of proteoglycan within the
cartilage matrix and is used as a means of assessing cartilage formation. Toluidine blue
is a cationic dye with high affinity for the negatively charged sulfate groups of
proteoglycans. Nuclei and cartilage stain a deep violet color whereas other tissues stain
a shade of pale blue.
Sagittal paraffins sections of E16 mouse skulls were prepared. Dewaxing of the
sections was completed using xylenes followed by rehydration through a succession of
decreasing concentrations of ethanol. Slides were stained using toluidine blue working
solution for 5 mins, followed by a water wash until the solution runs clear. The slides
were then dehydrated in a 37℃ oven for 20 mins. Xylene was used to clear the slides,
and coverslips were applied to the sections with ShurMount™ mounting medium.
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Figure 5: Representative microscope images of Alcian blue and Alizarin red embryo
skulls stained in different viewpoints. Red measure lines represent the parameter
evaluated in each viewpoint. Caudal viewpoint with mandibular angle and transverse
parameters (A). Coronal viewpoint with AP and transverse parameters (B). Sagittal
viewpoint with AP and mandibular length parameters (C).
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2.6 Immunohistochemistry
Immunohistochemistry was used to detect and localize three proteins: Sox9,
Beta-catenin, and Osteocalcin, in the tissue of E16 mouse skulls. Sox9 is an essential
regulator of chondrogenesis.66 Beta-catenin is a key downstream effector of GSK-3
action on the Wnt/beta-catenin signalling pathway.20 Osteocalcin is a marker of bone
development.95 The technique uses a two-step binding process; the first step employs a
specific primary antibody to bind the antigenic region located on the protein of interest.
The second step involves the binding of the primary antibody by a secondary antibody
conjugated to the enzyme horseradish peroxidase (HRP). HRP catalyzes the reaction
between the chromogen 3,3’-Diaminobenzidine (DAB) and hydrogen peroxide at the site
in the tissue section where the protein is located. The product of the reaction is oxidized
DAB which is an insoluble brown pigment that can be viewed under light microscopy.
Sagittal paraffin sections (5μm thickness) of E16 mouse skulls were prepared.
The process involves dewaxing the sections with xylenes and then rehydrating through a
succession of decreasing concentration of ethanol. To block endogenous peroxidase
from reacting with the chromogen and causing false positivity, a solution of hydrogen
peroxide in methanol is used. During tissue processing the antigenic determinant
(epitope) on the antigen can be imperceptible to antibodies, therefore 0.1% solution of
the non-ionic detergent Triton X-100 is used to improve antigen accessibility and
antibody binding. To reduce non-specific antibody binding, the tissue sections are
preincubated in a saline and goat serum solution. Primary antibodies: goat polyclonal
hSox9 (AF3075 R&D Systems), or rabbit polyclonal β-Catenin (bs-1165R Bioss
Antibodies), or rabbit polyclonal Osteocalcin (ab93876 Abcam) are bound to the tissue
section, overnight at 4°C. Removal of any unbound primary antibodies is achieved by
successive phosphate buffer saline (PBS) washes. Suitable HRP-conjugated secondary
antibodies are selected and added to the tissue in order to bind the primary antibodies.
A second series of washes using distilled water is completed to remove the unbound
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secondary antibodies. The remaining bound antibody-HRP complex is observed using a
DAB staining kit (DAKO). As soon as color becomes evident the reaction is stopped by
transferral of slides into water, followed by counterstaining with 0.5% methyl green and
mounting with the xylene-based media ShurMount™. Light microscopy was performed
using a Leica DM1000 microscope using Leica Application Suite Software (Leica, Wetzlar,
Germany).

2.7 Data Analysis
Following data collection (Appendix A) of the measurements for each embryo,
descriptive statistics including mean and standard deviation (SD) were calculated for
each litter trial. The software Statistical Product and Service Solutions (SPSS) version
27.0 (IBM Corporation, Armonk, NY, USA) was used to perform an Error Study and a
Paired Samples T Test analysis. Statistical significance was set at P<0.05. Qualitative
analysis was completed using E16 sagittal cross sections of the skull.
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Chapter 3

3

Results

3.1 Error Study
Due to a certain degree of subjectiveness involved when making twodimensional measurements of a three-dimensional mouse skull, an error study was first
conducted to assess reliability of the examiner’s measurements. Test-retest reliability
was assessed in terms intraclass correlation coefficient (ICC) using a two-way random
effects model. ICC values range from 0-1.00; values above 0.90 indicate excellent
reliability; those between 0.75-0.90 indicate good reliability; 0.50-0.75 have moderate
reliability; and those below 0.5 have poor reliability 96.
Data were gathered at two different time points 2 months apart to determine
intra-examiner reliability. Table 1 shows ICC for each parameter measured by the
examiner. The ICC values for all parameters ranged from 0.93 to 0.99. Excellent intrarater reliability was found for all parameters. The lowest reliability (0.93) is seen with
the transverse width measurements in the caudal viewpoint. The highest reliability
(1.00) is seen in AP measurements in both coronal and caudal viewpoints and the
transverse measurement in the coronal viewpoint.

Parameters
AP (sagittal)
AP (coronal)
Transverse (coronal)
Transverse (caudal)
Mandibular Angle
Mandible (sagittal)

ICC
0.99
0.99
0.99
0.93
0.95
0.95

Table 1: Intrarater correlation coefficient for each parameter.
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3.2 Craniofacial Skeleton Measurements
A total of 10 trials with each trial consisting of embryos from the same litter
were examined for skull and mandibular parameters. The number of embryos in each
trial ranged from 2 to 8. Visual examination of the stained specimens by naked eye
showed minimal differences between mutants and non-mutant skulls, whereas under
microscopic examination the size discrepancy between the two groups could be
distinguishable. Length of the craniofacial skeleton and the width of the cranial vault as
well as mandibular parameters were assessed using Alcian Blue and Alizarin Red stained
specimen under a microscope (Fig. 5). Following completion of the measurements, the
genotype of each embryo was revealed (Appendix B) and the associated features for
mutants (knock outs) vs nonmutants (control) was assessed. Genotypic wildtype and
heterozygote mice were both grouped into the control mice category because data from
this study showed no phenotypic differences between the two genotypes (Appendix C).
Mean measurement for all parameters between KO mice and control mice for
each trial were represented in scatterplots (Fig 9-14). The mean measurement, standard
deviation (SD), differences between means, and P-value for each parameter between
KO mice and control mice grouped amongst all trials is shown in Table 2. The values
from Table 2 were plotted in a bar graph format in Appendix D. The difference in AP
between the KOs and control mice across all trials was found to be significantly
different, with the mean AP measurements being 7.37mm and 8.30mm, respectively.

Figure 6: Representative images from the sagittal view of GSK-3 KO embryo skull (A) and
Control embryo skull (B)
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The mean reduction in size as measured in the transverse dimension was not as
large as the AP dimension between the two groups. The mutants had a mean transverse
dimension of 5.25mm while the wild type mean transverse width was 5.49mm. The two
groups did not show a significant difference in transverse width in the coronal view, but
did show a significant difference in the caudal view.

Figure 7: Representative images from the coronal view of GSK-3 KO embryo skull
(A) and Control embryo skull (B)

The greatest proportional reduction in size was seen in the mandibular AP
length with a difference of 0.79mm between the two groups. Mandibular length was
found to be significantly different with the control embryos having a mean mandibular
length of 4.62mm and the mutants having a mean mandibular length of 3.83mm. The
KO embryos also display a significantly greater angle between the hemi angular
processes with a mean of 81.39° versus the control embryos, which have a mean of
62.13°. The AP/Transverse ratio in the coronal viewpoint was found to be significantly
different between KOs and control mice.
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Figure 8: Representative images from the caudal view of GSK-3 KO embryo
skull (A) and Control embryo skull (B)

KO Mean

Control
Mean

Difference
(Control-KO)

P-value

AP (sagittal) mm
AP (coronal) mm
Transverse (coronal) mm
Transverse (caudal) mm
Mandible Length (sagittal)
mm
Mandibular Angle (caudal) °

7.37 (0.96)
7.37 (0.94)
5.25 (0.71)
5.24 (0.72)
3.83 (0.46)

8.30 (1.02)
8.30 (1.05)
5.49 (0.72)
5.49 (0.72)
4.62 (0.48)

0.93
0.93
0.24
0.25
0.79

<0.001*
<0.001*
0.06
0.033*
<0.001*

81.39 (6.24)

62.13 (3.29)

-19.26

<0.001*

AP/Transverse (coronal)

1.41 (0.06)

1.51 (0.06)

0.10

<0.001*

Table 2: Mean measurement (+/- SD) of GSK-3 KO vs Control mice averaged over 10
trials. A “*” denotes a statistically significant difference between the two groups.
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Figure 9: Comparison of mean AP length between GSK-3 KO and control mice across
10 trials in the sagittal viewpoint.

Figure 10: Comparison of mean AP length between GSK-3 KO and control mice across
10 trials in the coronal viewpoint.
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Figure 11: Comparison of mean transverse width between GSK-3 KO and control mice
across 10 trials in the coronal viewpoint.

Figure 12: Comparison of mean transverse width between GSK-3 KO and control mice
across 10 trials in the caudal viewpoint.
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Figure 13: Comparison of mean mandibular length between GSK-3 KO and control mice
across 10 trials in the sagittal viewpoint.

Figure 14: Comparison of mean mandibular angle between GSK-3 KO and control mice
in the caudal viewpoint.
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3.3 Qualitative Analysis of Toluidine Blue Stains and IHC
To understand the significant differences seen in the observations between KO
and control mice, histological analyses of the viscerocranium were performed using E16
Toluidine Blue stained sections (Fig. 16). Histological slides stained by Toluidine Blue, a
dye which has an affinity for acidic tissue components like proteoglycans and cartilage,
showed observable differences in the viscerocranium between both groups. At E16 the
palate of the control mice has closed compared to Gsk3a and Gsk3b KOs which display
defective palatal growth and fusion. Primordia of the lower incisor appear to be
unaffected in development in the GSK-3 KO mice. The mandibular section of the GSK-3
KOs shows a noticeable reduction in the size of Meckel’s Cartilage when compared to
the wild type embryonic mice at E16, a finding which is also duplicated in the IHC stains
(Fig. 17).
Immunohistochemistry was used to detect and localize the presence of Sox9,
beta catenin, and osteocalcin in the mandibular cross section (Figure 17). The number of
Sox9 positive cells appears greater in the control mice cross section compared to KO
mice. The difference in the number of Sox9 positive cells is primarily observed in and
around the lower incisor tooth primordia. Both groups show Sox9 positive cells localized
in MC, however, there appears to be no difference in the relative number of stained
cells between groups within the structure. Beta catenin positive cells appear to be
diffuse in their location within the cross sections of both groups, with some particular
localization in and around the vicinity of MC. There appears to be a difference in
intensity of the beta catenin staining between the two groups with a reduced intensity
seen in the KO group. The relative number of beta catenin stained cells in the KO group
appears to be increased primarily in and around MC, whereas, the control group shows
appears to show an increase in the number beta catenin stained cells in the lower
incisor tooth primordia. Osteocalcin staining shows a pattern similar in localization to
beta catenin with no apparent change in intensity of the stain between the groups. In
comparison to the KO group, the control group appears to show a mildly greater
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increase in the relative number of osteocalcin stained cells in the lower incisor
primordia.

Figure 15: Microscope images of Toluidine Blue stained E16 KO and control
embryo maxilla and mandible (n =1). Failure of palatal shelf (PS) fusion resulting
in cleft (Cl) seen in KO mice (C). Meckel’s Cartilage (MC) seen distal to incisor
tooth primordia (L1) and inferior to base of tongue (T) is smaller in size in KO
embryo than in control embryo (B and D).
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Figure 16: Localized expression of Sox9 (A/D), Beta Catenin (B/E), and Osteocalcin
(C/F) assessed in E16 GSK-3 KO and control embryo mandibles by IHC images (n=1).
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4

Discussion
The aim of this study was to evaluate any changes that occur to the
parameters of the craniofacial skeleton when both Gsk3a and Gsk3b are knocked
out exclusively in mouse cartilage.

4.1 Anterior-Posterior Craniofacial Size
Previous literature has discussed the importance of GSK-3α and GSK-3β as key
regulators of bone growth and normal skeletal development.67, 68 This study was novel in
the approach of assessing the craniofacial effects of prenatal ablation of both GSK-3
proteins in mouse cartilage. The anteroposterior dimension of the skull was most affected
in absolute length with a reduction of 0.93mm between the two groups. The reduction of
craniofacial AP size in GSK-3 KO mice is consistent with previous literature which also
points to multiple defected craniofacial bones that are contributing to the total reduction
of the AP size of global GSK-3 KO mice skulls. Szabo-Rogers et al. showed that in the
absence of Gsk3b, frontal bone primordium exhibits cell apoptosis and reduced cell
proliferation, leading to a reduction of frontal bone size.97 Liu et al. showed defects in the
palatine process of the maxilla and palatine bones of Gsk3b KO mice resulting in cleft
palate.29 We found similar results of incomplete closure of the palate when the maxillae
of E16 Gsk3a and Gsk3b KO embryos were examined with Toluidine blue staining.
Furthermore, the difference in AP length of the skull may be due to the mechanism of
ossification of the cranial base bones. Sung-Won Jin et al. propose that the increase in AP
length of the cranium is governed by the growth of the cranial base bones with active
response at the coronal suture.98 The cranial base ossifies through endochondral
ossification, a process, which Bali et al. has shown to be disrupted in juvenile cartilagespecific GSK-3 KO mice resulting in shorter long bones.67 The origin of reduction in the AP
size of the skull is difficult to determine on stained slides in our study due to differences
in staining intensity and undefined bony margins for the craniofacial bones. We speculate
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that the AP length reduction in GSK-3 KO mice may have multiple sites of causal origin
including the maxilla, frontal bone, and the cranial base bones.

4.2 Mandibular Length
Mandibular length was found to have the greatest proportional decrease out of
all the parameters examined in the KO and control groups. The mean difference in the
length of the mandible was 0.79mm which corresponds to a 1/6 th reduction in mean AP
length of the mandible in the KO group. To further investigate the significant difference
seen in mandibular length, Toluidine blue staining and IHC were performed on KO and
control mandibles. Toluidine blue sections at E16 show an observable difference in the
size of Meckel’s cartilage between the two groups, with the GSK-3 KO group displaying a
smaller MC (Fig. 15). Previous literature has shown that Meckel’s cartilage serves as a
template for ossification and regulates the length of the mandible.51 This is consistent
with our study’s finding of a reduced mandibular length in GSK-3 KO mice.
Additionally, Lei et al. and Stewart et al., have demonstrated that faulty
development of Meckel’s cartilage can result in cleft palate

76, 99

; a finding which is also

replicated in the Toluidine blue stains of GSK-3 KO mice in this study. Ricks et al. argues
that normal development of MC promotes the AP extension of the mandible which
successively allows the tongue to flatten and give way for the fusion of the palatal
shelves.100 It is tempting to speculate that the failure of the palate to fuse in GSK-3 KO
mice is due to defective growth of MC and the mandible. GSK-3’s intrinsic regulation in
the process of palatogenesis has been demonstrated by He et al., and clefting has been
observed in the palate of global GSK-3 KO mice.77 In this study, because the GSK-3 KO is
cartilage-specific and the process of palatogenesis does not require a cartilage
intermediate, we suspect that the palatal clefting observed in Gsk3a and Gsk3b KO mice
is not due to defective intrinsic GSK-3 regulation in palatogenesis.
IHC was completed to determine if a relationship between the GSK-3 regulated
proteins Sox9, beta-catenin, and osteocalcin and the mandibular anlage could explain the

37

shorter mandibular length observed in GSK-3 KO mice. CNC-specific deletion of SOX-9 has
been previously shown to result in the absence of Meckel’s cartilage and consequently
shorter mandibles.51 Results of this study show the relative number of Sox9 positively
stained cells in MC appears similar in both groups despite the size of MC being smaller in
the KO group. A causal relationship between Sox9 and the size of MC cannot be
determined in this study. Beta-catenin prenatal KO mutants have also been associated in
severe truncation of MC as well as defective growth of the rostral process of the mandible
and lower incisor.101 GSK-3 is a known negative mediator of Wnt/beta-catenin signaling
20

, thus an increase in beta-catenin positive cells was anticipated in GSK-3 KO mice. Beta

catenin signaling, amongst other cellular processes, stimulates apoptosis in
chondrocytes.102 An increase in beta-catenin positive cells appeared to occur around MC
in KO mice, possibly signifying an increase in apoptosis of MC chondrocytes (Fig. 16E).
Further experiments, such as TUNEL analysis may reveal whether an increase in apoptosis
is present in MC of KO mice. This may explain the truncated size of MC observed in GSK3 KO mice. A decrease in beta-catenin positive cells appeared to occur in the lower incisor
primordia of KO mice as well, this however, is likely due to the early developmental stage
in which the lower incisor is in. Beta-catenin signaling is primarily required for the later
tooth root formation stage.103 Osteocalcin is a protein secreted by osteoblasts that binds
to calcium and concentrates in bone.104 It is used as a biomarker for bone formation and
does not reach maximum levels until late mineralization stages.95 In vitro GSK-3 inhibition
has been previously shown to enhance osteoblast differentiation and bone formation,
thereby increasing levels of osteocalcin.81 Qualitative IHC analysis did not suggest a
change in the osteocalcin staining in the cross section of the prenatal mouse mandible
between the two groups. The absence of an observable change in osteocalcin staining is
likely due to the timepoint, E16.5 may be too early in the mineralization process to show
changes in osteocalcin levels. Another explanation may be the fact the KO of GSK-3 is
occurring in chondrocytes. Intramembranous bone formation of the body of the mandible
is affected less by the ablation, therefore, minimal change in osteocalcin levels would be
expected. Despite the reduction in size of MC, no change in the bone formation process
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is consistent with the current paradigm that a change in MC primarily effects the resultant
size of the mandible and not the process of bone formation itself. This study did not
evaluate condylar changes in the GSK-3 KO mice; thus, it is plausible that some of the
reduction seen in mandibular length is due to defective endochondral ossification at the
condylar head.

4.3 Transverse Dimension
The transverse dimension showed conflicting results in the coronal and caudal
viewpoints despite the means of both viewpoints being nearly identical for the KO
(5.25/5.24mm) and control (5.49/5.49mm) group. In the coronal view point the difference
in mean transverse width was found not to be statistically significant, whereas the mean
transverse width in the caudal viewpoint was statistically significant. In respect to the ICC,
the least reliable measurement was the transverse width in the caudal viewpoint. The
transverse values in the coronal viewpoint (P-value<0.001) are consistently more reliable
and accurate than the mean transverse caudal viewpoint values (P-value=0.033). The
developmental process of cranial vault ossification may provide an explanation for the
milder effects observed on skull width than length. The transverse dimension was
measured at the widest points of the skull, both points are located on the cranial vault’s
parietal bones. The development of the cranial vault bones is primarily governed by
intramembranous ossification 98, a process that, which unlike endochondral ossification,
does not use a pre-existing cartilage template. In this study the KO of GSK-3 was
performed in chondrocytes, which may explain why no significant difference was seen in
the transverse dimension between KO and control embryos.
A significant difference was found in the AP/transverse ratio in the coronal
viewpoint. The difference in ratios is primarily to due to change in the AP with minimal
change in the transverse. Due to the severity of consequences associated with changes
to the transverse dimension, which include cranial collapse of the brain’s housing unit, it
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is also possible that a compensating mechanism may be at play in holding the cranial
width.

4.4

Hemi-mandibular angle
The increase in the hemi mandibular angle supports our theory of compensation

to maintain the width of the craniofacial skeleton. The angular processes were chosen as
landmarks because they were found to be more discernible in the caudal view as
compared to the coronoid and condylar processes. Furthermore, growth of the angular
processes is governed by chondrocyte mediated endochondral ossification.105 The angle
formed between the angular processes of the mandible with a vertex at the symphysis
was found to be significantly larger in KO embryos when compared to control embryos.
Peripheral edema which has been noted in cardiac myocyte specific GSK-3 KO mice

106

,

could be affecting the cartilage specific GSK-3 KO mice in our study. It is possible that a
fluid increase in the neck could be acting as a compressive force widening the mandible.
We believe that the greater mandibular angle in KO embryos may be a feature of the
aforementioned compensating mechanism to maintain the width of the craniofacial
skeleton. Figure 17 outlines how the decrease in AP length is compensated by an increase
in the mandibular angle to hold the transverse dimension of craniofacial skeleton. An
increase in the mandibular width may act to hold the width of cranium via its articulation
point at the temporomandibular joint cavity. Alternatively, it is also feasible that the
transverse dimension of the cranium may be causing an increase in the mandibular angle
as the mandible shortens in length.
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Figure 17: Compensating mechanism of mandible from caudal view of
GSK-3 KO mice mandible (blue) vs. Control (orange). As AP length
decreases the mandibular angle increases to maintain the width at the
angular process.

4.5 Lower Incisor Primordia
An interesting finding to note in the IHC slides is the development of the lower
incisor tooth primordia in the GSK-3 KO group which appears to be delayed compared to
the control group. All three proteins examined appear to exhibit relatively fewer stained
cells/matrix in the lower incisor primordia for the GSK-3 KO group. Sox9, beta catenin,
and osteocalcin have all been previously implicated as being essential in tooth
development.107–109 Further evaluation of tooth developmental stage at different
timepoints between control and KO mice would be needed to confirm that the GSK-3 KO
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produces a developmental delay in the lower incisor primordia. Further research of GSK3’s role in the development of teeth would be interesting to investigate.

4.6 Clinical Significance
GSK-3’s ability to modulate the craniofacial bones is clinically relevant in
orthodontics. In order to achieve a functional and esthetic outcome in orthodontics the
craniofacial skeleton must be in harmony. Too great of a skeletal discrepancy may
produce a subpar esthetic outcome. Alternatively, a challenging attempt to camouflage
the skeletal discrepancy may result in an unstable occlusion. Understanding how GSK-3
can change the size of the craniofacial bones like the mandible may help orthodontists
develop adjunctive treatment modalities to assist in the correction of skeletal
discrepancies without the need for surgery. Several human diseases have been linked to
faulty GSK-3 activity including gestational110 and type 2 diabetes6, Alzheimer’s and
psychiatric disorders.6 This study provides a basis suggesting GSK-3’s involvement in
micrognathia and cleft palate. Research evaluating GSK-3 inhibitors has also been on the
rise. Studies involving administration of GSK-3 inhibitors in animal models of diabetes
have shown positive results in normalizing blood glucose levels.111,

112

The prenatal

evaluation of GSK-3 ablation on the craniofacial skeleton is important because a majority
of congenital craniofacial anomalies manifest in utero. This study demonstrates possible
prenatal craniofacial effects and consequences of delivering drugs that target GSK-3
during pregnancy. Future research should focus on evaluating the effects of GSK-3
inhibitors on mandibular length during the course of orthodontic therapy.
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4.7 Strengths and Limitations of the Study
One of the strengths of this study involved the investigator being blinded to
embryo genotypes prior to taking craniofacial measurements, which helped reduce
investigator bias. Error study demonstrated strong ICC for all parameters indicating good
reliability of measurements. A large trial size of 10 litters also ensured reliability of the
measures.
One of the weaknesses of this study lied in the validity of the measurements which
could not be corroborated. There was a certain degree of subjectiveness on the
investigators part when making measurements and accounting for yaw, pitch and roll of
the skulls. Micro-CT would have assisted in the validity of the measurements. Other
weaknesses included varying litter sizes (2-6) giving unequal weight to trial means. The
study was conducted on mice as a result data needs to be extrapolated to humans. Sex
effects were not considered since sexes cannot be distinguished morphologically at the
examined age. In addition, further analyses on the molecular and cellular basis of the
observed effects is required. We do not know the efficiency with which Cre catalyzed KO
of the GSK-3 genes in the specific skeletal structures. On the other hand, recent reports
of transdifferentiation of chondrocytes to osteoblasts 113 raise the possibility that
additional cell types other than chondrocytes were affected by this genetic manipulation
as well.
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Chapter 5

5

Conclusions

The aim of this study was to assess the effect of chondrocyte specific deletion of Gsk3a
and Gsk3b in embryonic mice on the size of the mandible and the antero-posterior (AP)
and transverse size of the prenatal craniofacial skeleton at E18.5. It was found that:
1. There was a significant reduction in AP size of the skull, and mandible in GSK-3
KO mice.
2. There was no significant change observed in the transverse dimension of the
skull between the KO and control groups.
3. The intramandibular angle between the right and left angular processes was
significantly greater in the KO mice.
4. At E16.5 GSK-3 KO mice display cleft palate and a reduction in size of Meckel’s
Cartilage compared to the control group.
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Appendices
Appendix A: Complete set of measurements for each embryo in all trials

Trial 1
Embryo

Skull AP
(sagittal)
mm

Skull AP
(coronal)
mm

Skull
Transverse
(caudal) mm

AP/Transverse
(coronal)

Mandibular
Angle
(caudal) °

Mandible
Length
(sagittal) mm

5.87

Skull
Transverse
(coronal)
mm
4

1-1

5.86

3.87

1.47

76.85

3.38

1-2
1-3

5.46

5.61

3.87

3.75

1.45

107.6

3.08

6.23

6.14

3.98

3.89

1.54

66.13

3.62

1-4

6.46

6.44

4.11

4.15

1.57

67.97

3.63

Skull
Transverse
(caudal) mm

AP/Transverse
(coronal)

Mandibular
Angle
(caudal) °

Mandible
Length
(sagittal) mm

Trial 2
Embryo

Skull AP
(sagittal)
mm

Skull AP
(coronal)
mm

2-1

8.95

8.9

Skull
Transverse
(coronal)
mm
5.49

5.56

1.62

53.59

4.56

2-2

8.62

8.64

5.33

5.4

1.62

NA

3.97

2-3

8.15

8.23

5.59

5.57

1.47

NA

NA

2-4

8.04

7.83

5.72

5.77

1.37

76.43

3.69

2-5
2-6

8.06
8.92

7.98
8.82

5.33
5.41

5.45
5.36

1.50
1.63

83.72
67.3

3.64
4.99

2-7
2-8

Excluded
7.96

Excluded
8.04

Excluded
5.17

Excluded
5.25

Excluded
1.56

67.47
76.84

4.74
3.66

Trial 3
Embryo

Skull AP
(sagittal)
mm

Skull AP
(coronal)
mm

Skull
Transverse
(coronal)
mm

Skull
Transverse
(caudal) mm

AP/Transverse
(coronal)

Mandibular
Angle
(caudal) °

Mandible
Length
(sagittal) mm

3-1

8.01

8.09

5.41

5.4

1.50

65.38

4.8

3-2

8.06

8.04

5.31

5.2

1.51

61.96

4.82

3-3

6.95

6.93

4.7

4.81

1.47

84.09

4.18

3-4

6.27

6.14

4.38

4.34

1.40

81.52

3.79

3-5

6.41

6.45

4.21

4.29

1.53

82.57

3.78
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Trial 4
Embryo

Skull AP
(sagittal)
mm

Skull AP
(coronal)
mm

Skull
Transverse
(coronal)
mm

Skull
Transverse
(caudal) mm

AP/Transverse
(coronal)

Mandibular
Angle
(caudal) °

Mandible
Length
(sagittal) mm

4-1

7.49

7.57

5.12

5.1

1.48

63.36

4.78

4-2

7.65

7.69

5.38

5.3

1.43

66.04

4.97

4-3

7.86

7.88

5.08

5.02

1.55

62.49

4.48

4-4

6.99

6.91

4.98

4.95

1.39

90.08

3.76

Skull AP
(sagittal)
mm

Skull AP
(coronal)
mm

Skull
Transverse
(coronal)
mm

Skull
Transverse
(caudal) mm

AP/Transverse
(coronal)

Mandibular
Angle
(caudal) °

Mandible
Length
(sagittal) mm

7.48

7.34

4.85

4.96

1.51

60.57

4.64

6.73

6.84

4.76

4.89

1.44

80.77

3.88

Trial 5
Embryo

5-1
5-2

Trial 6
Embryo

Skull AP
(sagittal)
mm

Skull AP
(coronal)
mm

Skull
Transverse
(coronal)
mm

Skull
Transverse
(caudal) mm

AP/Transverse
(coronal)

Mandibular
Angle
(caudal) °

Mandible
Length
(sagittal) mm

6-1

7.67

7.69

5.41

5.48

1.42

55.1

4.78

6-2

6.66

6.67

5.29

5.27

1.26

73.27

4.16

Trial 7
Embryo

Skull AP
(sagittal)
mm

Skull AP
(coronal)
mm

Skull
Transverse
(coronal)
mm

Skull
Transverse
(caudal) mm

AP/Transverse
(coronal)

Mandibular
Angle
(caudal) °

Mandible
Length
(sagittal) mm

7-1

7.76

7.83

5.52

5.44

1.42

82.64

3.86

7-2

9.01

8.99

6.1

5.93

1.47

61.59

4.69

7-3

8.56

8.6

5.77

5.46

1.49

86.64

4.14

7-4

9.16

9.21

6.13

6.09

1.50

Excluded

4.79

7-5

8.47

8.36

6.17

6.14

1.35

85.75

3.4

7-6

9.19

9.13

6.12

6.03

1.49

65.93

4.7
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Trial 8
Embryo

Skull AP
(sagittal)
mm

Skull AP
(coronal)
mm

Skull
Transverse
(coronal)
mm

Skull
Transverse
(caudal) mm

AP/Transverse
(coronal)

Mandibular
Angle
(caudal) °

Mandible
Length
(sagittal) mm

8-1

9.65

9.73

6.65

6.69

1.46

61.86

3.99

8-2

9

9.3

6.54

6.49

1.42

60.04

Excluded

8-3

8.06

8.14

5.73

5.76

1.42

81.2

3.02

8-4

8.31

8.26

5.78

5.82

1.43

77.79

Excluded

Skull
Transverse
(coronal)
mm
6.04
5.91

Skull
Transverse
(caudal) mm

AP/Transverse
(coronal)

Mandibular
Angle
(caudal) °

Mandible
Length
(sagittal) mm

5.99
5.99

1.39
1.60

75.23
59.38

4.49
5.22

Trial 9
Embryo

Skull AP
(sagittal)
mm

Skull AP
(coronal)
mm

9-1
9-2

8.4
9.53

8.38
9.48

Trial 10
Embryo

Skull AP
(sagittal)
mm

Skull AP
(coronal)
mm

Skull
Transverse
(coronal)
mm

Skull
Transverse
(caudal) mm

AP/Transverse
(coronal)

Mandibular
Angle
(caudal) °

Mandible
Length
(sagittal) mm

10-1

8.19

8.21

6.02

6.04

1.36

76.05

4.37

10-2

8.96

9.01

6.04

6.01

1.49

64.04

5.09
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Appendix B: Genotypes for individual embryos determined from PCR
Note: Both C and Het are used as controls in skeletal stains, they are indistinguishable
from each other by eye.
Trial
1

2

3

4

5

6

7

8

Embryo

Genotype

Status

1-1

GSK3αffβffCol2a1cre+/-

KO

1-2

GSK3αffβffCol2a1cre+/-

KO

1-3

GSK3αffβff

C

1-4

GSK3αf+βff

C

1-5

GSK3αf+βff

C

2-1

GSK3αf+βff

C

2-2

GSK3αffβffCol2a1cre+/-

KO

2-3

GSK3αffβffCol2a1cre+/-

KO

2-4

GSK3αffβffCol2a1cre+/-

KO

2-5

GSK3αffβff

3-1

GSK3αf+βffCol2a1cre+/-

Het

3-2

GSK3αf+βffCol2a1cre+/-

Het

3-3

GSK3αffβffCol2a1cre+/-

KO

3-4

GSK3αffβffCol2a1cre+/-

KO

3-5

GSK3αffβffCol2a1cre+/-

KO

4-1

GSK3αf+βff

4-2

GSK3αf+βffCol2a1cre+/-

Het

4-3

GSK3αf+βffCol2a1cre+/-

Het

4-4

GSK3αffβffCol2a1cre+/-

KO

5-1

GSK3αffβff

5-2

GSK3αffβffCol2a1cre+/-

6-1

GSK3αf+βff

6-2

GSK3αffβffCol2a1cre+/-

KO

7-1

GSK3αffβffCol2a1cre+/-

KO

7-2

GSK3αf+βffCol2a1cre+/-

Het

7-3

GSK3αffβffCol2a1cre+/-

KO

7-4

GSK3αf+βff

7-5

GSK3αffβffCol2a1cre+/-

7-6

GSK3αf+βff

8-1

GSK3αffβff

8-2

GSK3αf+βffCol2a1cre+/-

Het

8-3

GSK3αffβffCol2a1cre+/-

KO

C

C

C
KO
C

C
KO
C
C

8-4

(GSK3αffβffCol2a1cre+/-)

KO

9

9-1

GSK3αffβffCol2a1cre+/-

KO

9-2

GSK3αffβff

10

10-1

GSK3αffβffCol2a1cre+/-

KO

10-2

GSK3αf+βffCol2a1cre+/-

Het

C
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Appendix C: Heterozygotes vs Control

AP (sagittal) mm
AP (coronal) mm
Transverse (coronal) mm
Transverse (caudal) mm
Mandible Length (sagittal)
mm
Mandibular Angle (caudal)
°
AP/Transverse (coronal)

Heterozygote Control Mean
Mean (N=7)
(N=13)

P-value

8.36 (0.56)
8.43 (0.60)
5.69 (0.49)
5.62 (0.49)
4.81 (0.19)

8.28 (1.12)
8.26 (1.14)
5.38 (0.76)
5.39 (0.77)
4.49 (0.50)

0.86
0.73
0.36
0.51
0.17

63.08 (2.00)

62.61 (4.78)

0.81

1.48 (0.04)

1.54 (0.06)

0.082

Mean measurements (+/-SD) for Heterozygotes vs Controls grouped across all trials.
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Appendix D: Bar graphs for KO and Control mice mean measurements of parameters
across all trials

Comparison of mean AP length between GSK-3 KO and control mice in the sagittal
viewpoint.

Comparison of mean AP length between GSK-3 KO and control mice in the coronal
viewpoint.
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Comparison of mean transverse width between GSK-3 KO and control mice in the
coronal viewpoint.

Comparison of mean transverse width between GSK-3 KO and control mice in the caudal
viewpoint.
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Comparison of mean mandibular length between GSK-3 KO and control mice in the
sagittal viewpoint.

Comparison of mean mandibular angle between GSK-3 KO and control mice in the
caudal viewpoint.
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Appendix E: Mean measurement for each craniofacial parameter evaluated between
GSK-3 KO and control mice for trials 1-10
Trial 1
KO Mean
AP (sagittal) mm
AP (coronal) mm
Transverse (coronal) mm
Transverse (caudal) mm
AP/Transverse (coronal)
Mandibular Angle (caudal) °
Mandible Length (sagittal) mm

Control Mean
5.66
5.74
3.94
3.81
1.46
92.23
3.23

6.35
6.29
4.05
4.02
1.55
67.05
3.63

Trial 2
KO Mean
AP (sagittal) mm
AP (coronal) mm
Transverse (coronal) mm
Transverse (caudal) mm
AP/Transverse (coronal)
Mandibular Angle (caudal) °
Mandible Length (sagittal) mm

Control Mean
8.05
8.02
5.45
5.51
1.47
79.00
3.66

8.83
8.79
5.41
5.44
1.62
62.79
4.57

Trial 3
KO Mean
AP (sagittal) mm
AP (coronal) mm
Transverse (coronal) mm
Transverse (caudal) mm
AP/Transverse (coronal)
Mandibular Angle (caudal) °
Mandible Length (sagittal) mm

Control Mean
6.54
6.51

8.04
8.06

4.43
4.48
1.47
82.73
3.92

5.36
5.30
1.50
63.67
4.81
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Trial 4
KO Mean
AP (sagittal) mm
AP (coronal) mm
Transverse (coronal) mm
Transverse (caudal) mm
AP/Transverse (coronal)
Mandibular Angle (caudal) °
Mandible Length (sagittal) mm

Control Mean
6.99
6.91
4.98
4.95
1.39
90.08
3.76

7.67
7.71
5.19
5.14
1.49
63.96
4.74

Trial 5
KO Mean
AP (sagittal) mm
AP (coronal) mm
Transverse (coronal) mm
Transverse (caudal) mm
AP/Transverse (coronal)
Mandibular Angle (caudal) °
Mandible Length (sagittal) mm

Trial 6
Trial 6
AP (sagittal) mm
AP (coronal) mm
Transverse (coronal) mm
Transverse (caudal) mm
AP/Transverse (coronal)
Mandibular Angle (caudal) °
Mandible Length (sagittal) mm

Control Mean
6.73

7.48

6.84
4.76
4.89
1.44
80.77
3.88

7.34
4.85
4.96
1.51
60.57
4.64

KO Mean

Control Mean
6.66
6.67
5.29
5.27
1.26
73.27
4.16

7.67
7.69
5.41
5.48
1.42
55.1
4.78
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Trial 7
KO Mean
AP (sagittal) mm
AP (coronal) mm
Transverse (coronal) mm
Transverse (caudal) mm
AP/Transverse (coronal)
Mandibular Angle (caudal) °
Mandible Length (sagittal) mm

Control Mean
8.26
8.26
5.82
5.68
1.42
85.01
3.80

9.12
9.11
6.12
6.02
1.49
63.76
4.73

Trial 8
KO Mean
AP (sagittal) mm
AP (coronal) mm
Transverse (coronal) mm
Transverse (caudal) mm
AP/Transverse (coronal)
Mandibular Angle (caudal) °
Mandible Length (sagittal) mm

Control Mean
8.19
8.2
5.76
5.79
1.42
79.50
3.02

9.33
9.512
6.60
6.59
1.44
60.95
3.99

Trial 9
KO Mean
AP (sagittal) mm
AP (coronal) mm
Transverse (coronal) mm
Transverse (caudal) mm
AP/Transverse (coronal)
Mandibular Angle (caudal) °
Mandible Length (sagittal) mm

Control Mean
8.4
8.38
6.04
5.99
1.40
75.23
4.49

9.53
9.48
5.91
5.99
1.60
59.38
5.22
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Trial 10
KO Mean
AP (sagittal) mm
AP (coronal) mm
Transverse (coronal) mm
Transverse (caudal) mm
AP/Transverse (coronal)
Mandibular Angle (caudal) °
Mandible Length (sagittal) mm

Control Mean
8.19
8.21
6.02
6.04
1.37
76.05
4.37

8.96
9.01
6.04
6.01
1.49
64.04
5.09
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